Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts

Abstract excerpt

Preclinical models often fail to capture the diverse heterogeneity of human malignancies and as such lack clinical predictive power. Patient-derived tumor xenografts (PDX) have emerged as a powerful technology: capable of retaining the molecular heterogeneity of their originating sample. However, heterogeneity within a tumor is governed by both cell-autonomous (e.g., genetic and epigenetic heterogeneity) and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Cells and Metastasis
• Share to Cancer Genomics and Diagnostics
• Share to Cancer Research and Treatments